Hexarelin acetate is more effective than growth hormone releasing hormone (GHRH) yet it produces synergistic effects on GH release in combination with GHRH, resulting in "massive" increases in plasma GH levels even with only low doses.

Hexarelin reached phase II clinical trials for the treatment of growth hormone deficiency and congestive heart failure but did not complete development and was never marketed.

The three times daily intranasal Hexarelin administration was associated with significant biochemical changes and growth velocity in children.

The use of synthetic peptide like Hexarelin Acerate counteract the effects of Somatopause.

 
Somatopause is the gradual decline in the levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), s of the hypothalamic-pituitary axis (HPS axis).

Somatopause results in changes in the body, such as body composition changes like a decrease in lean body mass.

Hexarelin is a peptide similar to ghrelin that is naturally produced in the brain to stimulate growth hormone release from the pituitary gland.

A partial and reversible tolerance to the GH-releasing effects of examorelin occurs in long-term administration (50–75% decrease in efficacy over the course of weeks to months).